Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension

Ronald Tilton, T. A. Brock, R. A F Dixon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)1291-1308
Number of pages18
JournalExpert Opinion on Investigational Drugs
Volume10
Issue number7
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Nitric Oxide Donors
Pulmonary Hypertension
Vasodilator Agents
Heart Failure
Blood Vessels
Therapeutics
Connective Tissue Diseases
Pulmonary Circulation
Mitral Valve Stenosis
Acute Lung Injury
Calcium Channel Blockers
Epoprostenol
Vascular Resistance
Anticoagulants
Chronic Obstructive Pulmonary Disease
Lung Diseases
Endothelin Receptor Antagonists
Heart Diseases
Nitric Oxide
Cardiovascular Diseases

Keywords

  • Endothelin
  • Endothelin receptors
  • ET and ET antagonists
  • Nitric oxide
  • NO donors
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pharmacology

Cite this

Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. / Tilton, Ronald; Brock, T. A.; Dixon, R. A F.

In: Expert Opinion on Investigational Drugs, Vol. 10, No. 7, 2001, p. 1291-1308.

Research output: Contribution to journalArticle

@article{c065afcbc1a3479eaa09d370d4d1ff96,
title = "Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension",
abstract = "Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.",
keywords = "Endothelin, Endothelin receptors, ET and ET antagonists, Nitric oxide, NO donors, Pulmonary hypertension",
author = "Ronald Tilton and Brock, {T. A.} and Dixon, {R. A F}",
year = "2001",
doi = "10.1517/13543784.10.7.1291",
language = "English (US)",
volume = "10",
pages = "1291--1308",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension

AU - Tilton, Ronald

AU - Brock, T. A.

AU - Dixon, R. A F

PY - 2001

Y1 - 2001

N2 - Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.

AB - Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.

KW - Endothelin

KW - Endothelin receptors

KW - ET and ET antagonists

KW - Nitric oxide

KW - NO donors

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=0034940315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034940315&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.7.1291

DO - 10.1517/13543784.10.7.1291

M3 - Article

VL - 10

SP - 1291

EP - 1308

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 7

ER -